Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03157323
Other study ID # AAAQ9790
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 1, 2017
Est. completion date June 2026

Study information

Verified date February 2024
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to determine the feasibility of a 6-month low glycemic dietary intervention in children and adolescents undergoing treatment for acute lymphoblastic leukemia.


Description:

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy with survival exceeding 90%. However, treatment-related toxicity remains a clinical challenge during and after treatment. Evidence-based, nutritional interventions may minimize the development of nutrition-related toxicities, such as bone morbidities, hypertriglyceridemia, and obesity. To date, no effective interventions are available to prevent nutrition-related morbidities in children with ALL. Clinical studies evaluating the glycemic indices in other pediatric conditions have been encouraging. It is plausible that reducing the glycemic indices of diets during cancer treatment may have a profound clinical effect in this vulnerable pediatric population. Prior to the design and implementation of randomized, controlled trials, epidemiological data describing the Glycemic Index (GI) and Glycemic Load (GL) and the association with clinically important outcomes is needed. Additionally, the feasibility of a dietary intervention must also be explored within the setting of pediatric cancer. This study aims to determine the feasibility, measured by compliance to a low-GI diet, of a 6-month low glycemic dietary intervention in children and adolescents undergoing treatment for ALL. The proposed work will be used for the design and implementation of a multi-center nutritional intervention aimed at improving dietary intake during treatment and its effect on clinically important outcomes. Importantly, the information will be used to drive the formation of evidence-based nutritional guidelines for children with cancer, which will expand into the emerging field of individualized medicine for patients with cancer.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 88
Est. completion date June 2026
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender All
Age group 5 Years to 21 Years
Eligibility Inclusion Criteria: - Diagnosis of Acute Lymphoblastic Leukemia (B-Cell, T-Cell, or Mixed Phenotype) - Within 3 days of starting the induction phase of treatment for Acute Lymphoblastic Leukemia - Proficient in English or Spanish Exclusion Criteria: - Diagnosis of relapsed Acute Lymphoblastic Leukemia - Not meeting all of the inclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Low Glycemic Index Diet
The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.

Locations

Country Name City State
United States Roswell Park Cancer Institute Buffalo New York
United States Connecticut Children's Medical Center Hartford Connecticut
United States Columbia University New York New York
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Children's National Hospital Washington District of Columbia

Sponsors (3)

Lead Sponsor Collaborator
Columbia University American Cancer Society, Inc., Gabrielle's Angel Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of a 6-month low glycemic dietary intervention in children and adolescents undergoing treatment for ALL. Feasibility will be measured by compliance to a low glycemic index diet, which will be measured via 24 dietary recall, using the Automated Self-Administered 24-Hour Dietary Assessment Tool. A dietary recall will be taken at 7 timepoints from diagnosis to end of treatment; each recall will be defined categorically as high compliance (GI score <55), moderate compliance (GI score 56-69) and low compliance (GI score >70). Change in glycemic index score will show compliance. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Enrolling by invitation NCT05622682 - Vaccine Immune Recovery After Leukemia
Not yet recruiting NCT05029531 - Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021) Phase 3
Not yet recruiting NCT06107478 - Parental Perception of Their Child's Emotional Quality of Life in Paediatric Oncology Before and After "Magic Massages"
Recruiting NCT04049383 - CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL Phase 1
Active, not recruiting NCT04472286 - Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
Completed NCT05973032 - MRD Detection by NGS in Pediatric B-ALL
Completed NCT05032716 - EFFECT OF TREADMILL TRAINING ON BALANCE AFTER CHEMOTHERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA N/A
Not yet recruiting NCT05809284 - Determining the Mechanisms of Loss of CAR T Cell Persistence
Recruiting NCT03035344 - Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL) N/A
Terminated NCT03705507 - International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia Phase 1/Phase 2
Recruiting NCT04325841 - Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children Phase 2
Active, not recruiting NCT03020030 - Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Phase 3
Not yet recruiting NCT06257394 - Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea Phase 2
Recruiting NCT04996160 - Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) Phase 1
Recruiting NCT03643276 - Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Phase 3
Active, not recruiting NCT04088864 - CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Phase 1
Completed NCT04770922 - Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia
Not yet recruiting NCT04228393 - The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China Phase 2/Phase 3
Recruiting NCT04400071 - Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment N/A